Yang Ying's archival value lies in providing a sample of how a Chinese private entrepreneur navigates cycles and achieves diversification. Starting with a private school in 1994, betting on biomedicine in 1997, and entering real estate in 2001, each step was taken at the industry's nascent stage, yet she never chased trends. Her long-termist approach from education was replicated in pharma and real estate, ultimately nurturing a STAR Market listed company. Her story is not aggressive cross-industry leaps but steady extension based on industrial judgment, which is why this column classifies her as a 'New Business Leader.'

Yang Ying's business career began in 1994 when she founded Xiamen Yingcai School, entering the private education sector. At a time when private education was nascent, she focused on teaching systems and faculty development, making the school a benchmark in southern Fujian. In 1997, she strategically invested in Amoytop Biotech, entering biomedicine and supporting R&D for years. In 2001, she entered Beijing real estate, founding Xinyingcai Real Estate. In 2007, she established Xinyingcai Holding Group, integrating education, pharma, and real estate into a synergistic diversified system. In 2020, Amoytop Biotech listed on the STAR Market, a key milestone in her business empire. ^{[1] [2] [3]}

Yang Ying's business philosophy is rooted in the long-term investment experience in education. She believes that quality industries cannot be rushed; only sustained investment and steady refinement build industry barriers. She rejects short-term trends and speculation, insisting on real-economy cultivation. In biomedicine, she accompanied Amoytop for over two decades, supporting its innovation; in real estate, she focuses on quality development. She once said, 'The mission of biomedicine is to make good medicines available and affordable to more people.' ^[6] This long-termist thinking runs through her diversification, enabling synergy among business segments and forming a stable ecosystem. ^{[1] [2] [6]}

Yang Ying's business layout has significantly impacted the regional economy. Amoytop Biotech, as a benchmark biomedical enterprise in Fujian, has driven regional innovative drug R&D. Her commercial achievements and philanthropic contributions have earned recognition: in 2025, she topped the Zhangzhou rich list with 13 billion RMB, with cumulative donations exceeding 76 million, covering education aid, serious illness assistance, and rural development. She donated 3 million for disaster recovery and 1.2 million for the Pinghe County Women and Children Center. Her education segment has been rated 'Top 10 Influential Brands in Chinese Private Education,' and her biomedical segment has been recognized as a 'National High-tech Enterprise.' ^{[4] [5] [7]} Her thirty years of cultivation exemplify the enterprising spirit and responsibility of new-era Min merchants. ^{[1] [4] [5]}

Yang Ying leaves a business proposition: how to maintain long-termist resolve across diversified industries. She proved that education, pharma, and real estate are not isolated tracks but can synergize through patience and resource integration. Her success lies not in catching a trend but in judging the industry's endgame and investing persistently. From private school to STAR Market, she embedded personal choices into regional economy and era demands, offering a replicable path: rooted in real economy, driven by innovation, and giving back to society.